We recently published an article titled 9 High Growth Canadian Stocks to Buy.  SNDL Inc. (NASDAQ:SNDL) is among the high-growth Canadian stocks to buy. The company operates in the Canadian adult-use cannabis market through a diversified business model that includes Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. SNDL is also involved in the production, distribution, and sale of cannabis products, giving it exposure to multiple parts of the value chain. This diversified structure allo ...

President Donald Trump's recent executive order urging the Department of Justice to reschedule cannabis to Schedule 3 is being hailed as the "most consequential federal cannabis policy shift" in over 50 years.Dan Ahrens, portfolio manager of the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) , says the move could finally dismantle the crippling tax regime that has stifled American cannabis operators for decades.The End Of ‘Narcotics Trafficker’ StatusAhrens told Yahoo Finance that the immediate financial ca ...

Industry Overview - The cannabis sector is experiencing growth despite historical volatility, with expectations for significant developments by 2026 that could benefit shareholders [1][2] - Recent legislative changes in the U.S., including the reversal of the 2018 farm bill and an executive order to reschedule cannabis, have sparked speculation about the future profitability for legal operators [2] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally. Recently entered the Netherlands market by acquiring CanAdelaar B.V., the largest cannabis company in the Netherlands, which is seen as a strategic move to expand its footprint in Europe [3][4][5] - **Aurora Cannabis Inc.**: Focuses on the production and distribution of cannabis products. The company has made significant advancements in disease resistance research, moving from research to production trials of cultivars with verified PM2 resistance [6][7][8] - **SNDL Inc.**: Engages in the production and sale of cannabis products for the adult-use market in Canada. Recently received approval for a share repurchase program, allowing the company to repurchase up to C$100 million of its outstanding common shares [9][10]

Group 1 - SNDL Inc. has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM Inc. [1] - This transaction marks the first closing under the amended and restated arrangement agreement dated December 15, 2025, with a second closing anticipated in the first half of 2026 for 27 additional stores in Ontario, pending regulatory approvals [2] - SNDL is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer, with various retail banners and consumer-facing cannabis brands [3] Group 2 - 1CM Inc. operates as a retailer of cannabis and liquor in Canada, focusing on developing cash-flow positive locations and pursuing growth through organic development and mergers and acquisitions [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM, maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [2] - Following the announcement of the amended acquisition agreement, SNDL's stock price fell by $0.29 per share, or 13.12%, closing at $1.92 per share on December 15, 2025 [3]

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. (“SNDL” or the “Company”) (NASDAQ: SNDL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether SNDL and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 15, 2025, SNDL a ...

Core Viewpoint - President Donald Trump's executive order marks a significant shift in federal cannabis policy, directing federal agencies to loosen regulations on marijuana [1] Regulatory Changes - The order instructs U.S. Attorney General Pam Bondi to expedite the rescheduling of marijuana to Schedule III under the Controlled Substances Act, aligning it with common painkillers but not fully legalizing it [2] - Marijuana's current classification as a Schedule I substance has limited research opportunities, and reclassification aims to enhance studies on safety and effectiveness, particularly for vulnerable populations [4] Access to CBD Products - The order outlines steps to improve access to hemp-derived cannabinoid products, especially cannabidiol (CBD), which currently lacks a clear regulatory pathway through the FDA [5] - It directs the White House Deputy Chief of Staff to collaborate with Congress to expand access to full-spectrum CBD products while restricting those posing health risks [6] Political Reactions - Senate Minority Leader Chuck Schumer supports the order, viewing it as a positive step, but emphasizes the need for further decriminalization and easing banking regulations for the cannabis industry [7] - Conversely, some Republican senators, including Ted Budd, criticize the order as shortsighted and potentially harmful to youth [7][8] Market Reactions - Cannabis stocks initially surged following the announcement but retreated by the close, attributed to the lack of expected cannabis banking provisions in the order [9] - Despite the retreat, major cannabis stocks have seen significant gains throughout the month in anticipation of the executive order [11]

SNDL (SNDL) shares gained nearly 12% on Wednesday. Dec. 16 following reports that President Donald Trump could reclassify cannabis as a “Schedule III” drug by the end of this week. The U.S. government is considering a policy shift that would offer some seniors access to cannabis products under Medicare coverage as well, the reports added. More News from Barchart SNDL stock has been a volatile investment this year. Despite a sharp rally on Tuesday, it’s down more than 25% versus its year-to-date high in ...

Core Points - SNDL Inc. and 1CM Inc. have entered into an amended and restated arrangement agreement to acquire 32 cannabis retail stores for a total purchase price of $32.2 million in cash [1][3] Group 1: Transaction Details - The transaction will be completed in two stages: the first closing will involve 5 stores in Alberta and Saskatchewan, while the second closing will involve 27 stores in Ontario [2] - The purchase price for the first closing is set at $5.0 million, and for the second closing at $27.2 million, with the total purchase price remaining unchanged [3] - The deadline for completing the transaction has been extended from December 31, 2025, to May 31, 2026 [2] Group 2: Shareholder and Court Approvals - 1CM's shareholders voted overwhelmingly in favor of the transaction, and a final court order was obtained on June 18, 2025 [4] - A court hearing is scheduled for January 5, 2026, to seek approval for the amendments to the transaction [4] Group 3: Financial Implications - 1CM plans to return a portion of the net proceeds from the transaction to its shareholders after the second closing [5] - The net proceeds from the first closing are expected to cover transaction costs and working capital [5] Group 4: Company Backgrounds - SNDL Inc. is one of the largest vertically integrated cannabis companies in Canada, with a diverse portfolio of retail brands and products [6] - 1CM Inc. operates cannabis and liquor retail locations and aims to continue expanding through organic growth and future mergers and acquisitions [7]

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands (TLRY.US) rising over 32%, Canopy Growth (CGC.US) increasing over 23%, SNDL (SNDL.US) up over 19%, Aurora Cannabis (ACB.US) gaining over 11%, and Cronos Group (CRON.US) climbing over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower harm category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) experienced a gain of over 19% [1] Group 2 - Aurora Cannabis (ACB.US) increased by more than 11% [1] - Cronos Group (CRON.US) rose by over 5% [1] - Reports indicate that Trump is considering moving cannabis from Schedule I to Schedule III, indicating a potential shift in regulatory stance [1]